AAUM (Average Assets Under Management) of ₹48.15 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 77.6% | 78.9% | ▲ +1.3% |
| Healthcare Services | 21.2% | 20.4% | ▼ -0.8% |
| Healthcare Equipment & Supplies | 1.0% | 1.0% | ● +0.0% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 78.9% | 79.8% | ▲ +1.0% |
| Healthcare Services | 20.4% | 19.3% | ▼ -1.2% |
| Healthcare Equipment & Supplies | 1.0% | 1.0% | ● 0.0% |
Comparing Aug 2026 → Sep 2026
| # | Stock | Sector | Weight (Sep 2026) |
|---|---|---|---|
| 1 | Anthem Biosciences Limited ₹74.66 L |
Pharmaceuticals & Biotechnology | 1.42% |
| # | Stock | Sector | Last Weight (Aug 2026) |
|---|---|---|---|
| 1 | Pfizer Limited ₹54.34 L |
Pharmaceuticals & Biotechnology | 1.07% |
| # | Stock | Sector | Aug 2026 | Sep 2026 | Change |
|---|---|---|---|---|---|
| 1 | Laurus Labs Limited ₹6.22 Cr |
Pharmaceuticals & Biotechnology | 11.23% | 11.83% | +0.60% |
| 2 | Wockhardt Limited ₹1.41 Cr |
Pharmaceuticals & Biotechnology | 2.34% | 2.68% | +0.34% |
| 3 | Mankind Pharma Limited ₹2.29 Cr |
Pharmaceuticals & Biotechnology | 4.11% | 4.35% | +0.24% |
| 4 | Ajanta Pharma Limited ₹1.33 Cr |
Pharmaceuticals & Biotechnology | 2.29% | 2.53% | +0.24% |
| 5 | Sai Life Sciences Limited ₹1.70 Cr |
Pharmaceuticals & Biotechnology | 3.03% | 3.23% | +0.20% |
| 6 | Abbott India Limited ₹1.14 Cr |
Pharmaceuticals & Biotechnology | 2.03% | 2.17% | +0.14% |
| 7 | Acutaas Chemicals Ltd ₹1.37 Cr |
Pharmaceuticals & Biotechnology | 2.47% | 2.61% | +0.14% |
| 8 | Krishna Institute Of Medical Sciences Limited ₹1.61 Cr |
Healthcare Services | 2.95% | 3.06% | +0.11% |
| 9 | Dr. Lal Path Labs Limited ₹1.25 Cr |
Healthcare Services | 2.27% | 2.38% | +0.11% |
| 10 | Granules India Limited ₹1.01 Cr |
Pharmaceuticals & Biotechnology | 1.81% | 1.92% | +0.11% |
| # | Stock | Sector | Aug 2026 | Sep 2026 | Change |
|---|---|---|---|---|---|
| 1 | Fortis Healthcare Limited ₹3.23 Cr |
Healthcare Services | 7.12% | 6.15% | -0.97% |
| 2 | Biocon Limited ₹2.08 Cr |
Pharmaceuticals & Biotechnology | 4.43% | 3.96% | -0.47% |
| 3 | Lupin Limited ₹3.97 Cr |
Pharmaceuticals & Biotechnology | 8.01% | 7.57% | -0.44% |
| 4 | Glenmark Pharmaceuticals Limited ₹2.83 Cr |
Pharmaceuticals & Biotechnology | 5.63% | 5.39% | -0.24% |
| 5 | Aster DM Healthcare Limited ₹1.50 Cr |
Healthcare Services | 3.05% | 2.86% | -0.19% |
| 6 | Neuland Laboratories Limited ₹1.48 Cr |
Pharmaceuticals & Biotechnology | 2.99% | 2.82% | -0.17% |
| 7 | GlaxoSmithKline Pharmaceuticals Limited ₹92.41 L |
Pharmaceuticals & Biotechnology | 1.90% | 1.76% | -0.14% |
| 8 | Narayana Hrudayalaya Limited ₹99.75 L |
Healthcare Services | 1.99% | 1.90% | -0.09% |
| 9 | Syngene International Limited ₹55.90 L |
Healthcare Services | 1.15% | 1.06% | -0.09% |
| 10 | Aurobindo Pharma Limited ₹3.72 Cr |
Pharmaceuticals & Biotechnology | 7.16% | 7.09% | -0.07% |
30 stocks — Sep 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹6.22 Cr |
Pharmaceuticals & Biotechnology |
11.83%
|
|
| 2 |
₹3.97 Cr |
Pharmaceuticals & Biotechnology |
7.57%
|
|
| 3 |
₹3.72 Cr |
Pharmaceuticals & Biotechnology |
7.09%
|
|
| 4 |
₹3.23 Cr |
Healthcare Services |
6.15%
|
|
| 5 |
₹2.83 Cr |
Pharmaceuticals & Biotechnology |
5.39%
|
|
| 6 |
₹2.51 Cr |
Pharmaceuticals & Biotechnology |
4.78%
|
|
| 7 |
₹2.29 Cr |
Pharmaceuticals & Biotechnology |
4.35%
|
|
| 8 |
₹2.16 Cr |
Pharmaceuticals & Biotechnology |
4.11%
|
|
| 9 |
₹2.08 Cr |
Pharmaceuticals & Biotechnology |
3.96%
|
|
| 10 |
₹1.86 Cr |
Pharmaceuticals & Biotechnology |
3.54%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.